Questcor Pharmaceuticals M&A Summary
Questcor Pharmaceuticals has acquired 3 companies of its own. It has also divested 1 asset.
Questcor Pharmaceuticals’ largest acquisition to date was in 2013, when it acquired Rights to Synacthen for $60M. It’s largest disclosed sale occurred in 2019, when it sold BioVectra to H.I.G. Private Equity for $250M. Questcor Pharmaceuticals has acquired in 1 US state, and 2 countries. The Company’s most targeted sectors include life science (67%) and healthcare services (34%).
M&A Summary
-
M&A Total Activity4
- M&A Buy Activity3
- M&A Sell Activity1
- Total Sectors Invested 2
- Total Countries Invested 2
- M&A Buy/Sell Connections 3
Unlimited Searches
